When does tirzepatide’s patent protection expire?
Tirzepatide (the active ingredient in Mounjaro/Zepbound) has multiple layers of patent protection, so the “expiration date” depends on which specific patent(s) and jurisdiction you mean (brand patents vs. manufacturing process vs. formulation vs. method-of-use). Public patent listings commonly show the latest US patent expirations for tirzepatide falling in the 2030s, not immediately in the near term.
For a US-focused view of key tirzepatide patents and their estimated expiration timing, see DrugPatentWatch’s tirzepatide entry here: https://www.drugpatentwatch.com/p/tirzepatide
What patents drive the US expiration date for tirzepatide?
In the US, different patents can control market exclusivity depending on what’s being protected, such as:
- Method-of-use claims (how the drug is used to treat a condition)
- Composition/formulation claims (the drug product itself, including specific formulations)
- Process/manufacturing claims (how the active ingredient is made)
Because generic or biosimilar challengers usually target the specific weak points in the patent set, the controlling patent expiration date is often the one that remains in force the longest in the relevant claim category.
Does regulatory exclusivity (FDA) change the effective launch date for competitors?
Even if a patent expires, FDA-related exclusivity (like periods tied to approvals) can affect when a competitor can market a product. Patent expiration is one part of the timing; regulatory exclusivity and the status of any ongoing patent challenges can extend the practical “wait time.”
If you want, tell me whether you’re asking about:
- the latest US patent expiration date overall, or
- the date for a specific claim/patent number, or
- when a generic/biosimilar could launch in the US,
and I can narrow the answer accordingly.
Sources used for the US patent timeline
DrugPatentWatch (tirzepatide patent listings and expiration timing): https://www.drugpatentwatch.com/p/tirzepatide